Originally published by Crystal Pharmatech. Republished with company attribution. Original technical perspectives, references and source links are retained.

Many small-molecule programs fail to progress beyond Phase I. In many cases, this is not because the molecule or target biology is fundamentally wrong, but because the formulation never enabled a fair test of the biology.

Insufficient exposure, variable bioavailability, or release profiles misaligned with the disease mechanism or the target product profile (TPP) frequently prevent meaningful pharmacodynamic interpretation. Once clinical studies begin, correcting these limitations is often difficult, slow, and expensive.

Formulation decisions made early therefore set clinical and lifecycle risk.

A CMC Perspective: Where Risk Is Actually Created

In early development, CMC risk is often framed around timelines and execution. In practice, however, the highest-impact risks are introduced before GMP execution begins, during:

  • Solid-form selection
  • Biopharmaceutic assessment
  • Early formulation design

These decisions directly influence:

  • Achievable exposure
  • Dose flexibility
  • Clinical interpretability
  • Scalability and late-stage viability

At Crystal Pharmatech, we view early-stage CMC success as a function of decision quality, not throughput.

First-Time-Right Formulation: What We Mean

First-Time-Right formulation is not about optimizing speed to first-in-human. It is about designing formulation strategies that remain valid as programs advance.

At Crystal Pharmatech, solid-state research, polymorph/salt/cocrystal screening and selection, preformulation, crystallization, and formulation development are designed as one integrated scientific system.

In practice, this means:

  • Formulation strategies are tailored to disease-relevant exposure, not just manufacturability
  • Release profiles are aligned with the therapeutic mechanism and clinical hypothesis
  • Phase I formulations are evaluated against Phase II+ expectations, not treated as disposable solutions
  • Early formulation choices are made to minimize disruptive reformulation later in development

The objective is to preserve clinical momentum while reducing downstream technical and regulatory risk.

Enabled by the M3 Framework

Crystal's formulation strategy is guided by the M3 framework, which integrates formulation decisions across three interdependent dimensions:

Molecule Clinical needs, DMPK understanding, pharmacodynamics, safety, and the molecular profile define what exposure is required to meaningfully test the biology.

Material API solid form, physicochemical and biopharmaceutical properties, excipient functionality, stability, and process-fit composition determine whether that exposure can be delivered reliably and reproducibly.

Medicine TPP-driven design, critical quality attributes (CQAs), critical process parameters (CPPs), and a durable drug product control strategy ensure that the formulation can scale and remain viable across development stages.

Formulation decisions are evaluated across all three dimensions simultaneously—not optimized in isolation.

Specialty CRO/CDMO by Design

Crystal Pharmatech operates as a specialty CRO/CDMO, intentionally focused on the most decision-intensive stages of development.

Rather than offering maximal service breadth, we concentrate depth and senior scientific oversight in areas where early decisions disproportionately influence clinical success.

This specialization allows us to:

  • Go deeper where risk is created
  • Maintain consistent scientific ownership of formulation strategy
  • Support programs before scale and execution dominate decision-making

Crystal often complements one-stop-shop CDMOs by helping ensure that formulation foundations are correct before programs enter execution-heavy phases.

Global Execution, Consistent Science

Solid-state research, polymorph/salt/cocrystal screening and selection, preformulation, and crystallization development are supported from Cranbury, New Jersey or Suzhou, China. Formulation development and GMP manufacturing are supported from Toronto, Canada or Suzhou, China.

Our geographic footprint provides flexibility in execution and supply strategy, while maintaining consistent scientific assumptions and lifecycle intent.

The science does not change with location.

When to Engage

Crystal Pharmatech is typically engaged when teams want to:

  • Pressure-test whether early formulation strategies can survive beyond Phase I
  • Align solid-state and formulation decisions with clinical objectives and TPP
  • Reduce the risk of late-stage reformulation or clinical ambiguity
  • Bring senior formulation judgment into early development decisions

Closing Thought

First-Time-Right formulation is ultimately about respecting the cost of early decisions.

When formulation is designed with full lifecycle intent—grounded in Molecule, Material, and Medicine—programs are better positioned to generate interpretable clinical data and progress with confidence.

Read the original article and source figures